Literature DB >> 20425040

Ependymomas in adults.

Mark R Gilbert1, Roberta Ruda, Riccardo Soffietti.   

Abstract

Ependymomas are rare primary central nervous system tumors in adults. They occur most commonly in the spinal cord, where histopathologic evaluation is critical to differentiate the grade I myxopapillary ependymoma from the grade II ependymoma or grade III anaplastic ependymoma. Brain ependymomas are either grade II or III. Treatment for all grades and types includes maximum surgical resection. For myxopapillary ependymoma, complete removal while maintaining capsule integrity may be curative. Some grade II ependymomas may be observed carefully after imaging confirms complete resection, but grade III tumors require adjuvant radiation treatment. Radiation commonly is given to the region of tumor, except in cases in which there is imaging or cerebrospinal fluid evidence of tumor dissemination. Chemotherapy has not been studied extensively, although most reports suggest only modest benefit. Ongoing laboratory studies have uncovered important signal transduction pathways that may be better therapeutic targets, leading to the development of clinical trials using targeted agents.

Entities:  

Mesh:

Year:  2010        PMID: 20425040     DOI: 10.1007/s11910-010-0109-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  59 in total

1.  Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.

Authors:  I Rojas-Marcos; D Calvet; P Janoray; J Y Delattre
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

2.  Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.

Authors:  Piergiorgio Modena; Elena Lualdi; Federica Facchinetti; Joris Veltman; James F Reid; Simone Minardi; Irene Janssen; Felice Giangaspero; Marco Forni; Gaetano Finocchiaro; Lorenzo Genitori; Flavio Giordano; Riccardo Riccardi; Eric F P M Schoenmakers; Maura Massimino; Gabriella Sozzi
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

3.  High failure rate in spinal ependymomas with long-term follow-up.

Authors:  Daniel R Gomez; Brian T Missett; William M Wara; Kathleen R Lamborn; Michael D Prados; Susan Chang; Mitchel S Berger; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

4.  Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma.

Authors:  David W Hamilton; Meryl E Lusher; Janet C Lindsey; David W Ellison; Steven C Clifford
Journal:  Cancer Lett       Date:  2004-12-25       Impact factor: 8.679

5.  Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH.

Authors:  Judith W M Jeuken; Sandra H E Sprenger; Job Gilhuis; Hans L J M Teepen; Andre J Grotenhuis; Pieter Wesseling
Journal:  J Pathol       Date:  2002-06       Impact factor: 7.996

6.  Intracranial ependymomas: an analysis of prognostic factors and patterns of failure.

Authors:  Arnold C Paulino; B-Chen Wen; John M Buatti; David H Hussey; Weining K Zhen; Nina A Mayr; Arnold H Menezes
Journal:  Am J Clin Oncol       Date:  2002-04       Impact factor: 2.339

7.  alpha(v)beta(3) Integrin in central nervous system tumors.

Authors:  Michael Lim; Samira Guccione; Terri Haddix; Leroy Sims; Samuel Cheshier; Pauline Chu; Hannes Vogel; Griffith Harsh
Journal:  Hum Pathol       Date:  2005-06       Impact factor: 3.466

8.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.

Authors:  Blanca Suarez-Merino; Mike Hubank; Tamas Revesz; William Harkness; Richard Hayward; Dominic Thompson; John L Darling; David G T Thomas; Tracy J Warr
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

9.  Recurrent spinal ependymoma showing partial remission under Imatimib.

Authors:  N Fakhrai; P Neophytou; K Dieckmann; A Nemeth; D Prayer; J Hainfellner; C Marosi
Journal:  Acta Neurochir (Wien)       Date:  2004-09-13       Impact factor: 2.216

10.  Bevacizumab for recurrent ependymoma.

Authors:  R M Green; T F Cloughesy; R Stupp; L M DeAngelis; E A Woyshner; D E Ney; A B Lassman
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

View more
  51 in total

1.  Predictors of survival among older adults with ependymoma.

Authors:  E Susan Amirian; Terri S Armstrong; Mark R Gilbert; Michael E Scheurer
Journal:  J Neurooncol       Date:  2011-09-28       Impact factor: 4.130

2.  Solid-cystic cortical ependymoma: a diagnostic dilemma.

Authors:  Moeinadin Safavi; Mohammad Vasei; Zohreh Habibi
Journal:  Childs Nerv Syst       Date:  2021-01-06       Impact factor: 1.475

3.  Histologic grade and extent of resection are associated with survival in pediatric spinal cord ependymomas.

Authors:  Michael Safaee; Michael C Oh; Joseph M Kim; Derick Aranda; Phiroz E Tarapore; Tene A Cage; Nalin Gupta; Andrew T Parsa
Journal:  Childs Nerv Syst       Date:  2013-05-16       Impact factor: 1.475

4.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Authors:  Elizabeth Vera-Bolanos; Kenneth Aldape; Ying Yuan; Jimin Wu; Khalida Wani; Mary Jo Necesito-Reyes; Howard Colman; Girish Dhall; Frank S Lieberman; Philippe Metellus; Tom Mikkelsen; Antonio Omuro; Sonia Partap; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2014-08-13       Impact factor: 12.300

Review 5.  Ependymomas: development of immunotherapeutic strategies.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2013-10       Impact factor: 4.618

6.  (18)F-FDG PET-CT for Detection of Recurrent Spinal Ependymoma.

Authors:  Abhinav Singhal; Punit Sharma; Sellam Karunanithi; Bangkim Chandra Khangembam; Suhas Singla; Chandrasekhar Bal; Rakesh Kumar
Journal:  Nucl Med Mol Imaging       Date:  2012-09-28

7.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas.

Authors:  Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

8.  A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma.

Authors:  Ian David Connolly; Yingmei Li; Wenying Pan; Eli Johnson; Linya You; Hannes Vogel; John Ratliff; Melanie Hayden Gephart
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

9.  Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007.

Authors:  E Susan Amirian; Terri S Armstrong; Kenneth D Aldape; Mark R Gilbert; Michael E Scheurer
Journal:  Neuroepidemiology       Date:  2012-07-28       Impact factor: 3.282

10.  Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.

Authors:  Roberta Rudà; Chiara Bosa; Michela Magistrello; Federica Franchino; Alessia Pellerino; Valentina Fiano; Morena Trevisan; Paola Cassoni; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2015-08-30       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.